- Home
- BHVN
BHVN
Biohaven Ltd.
as 07-26-2024 4:00pm EST
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. Its products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | NEW HAVEN |
| Market Cap: | 3.0B | IPO Year: | 2017 |
| Target Price: | $54.71 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -6.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.45 - $62.21 | Next Earning Date: | 08-06-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | -75.21% |
Stock Insider Trading Activity of Biohaven Ltd. (BHVN)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Car Bruce | BHVN | Chief Scientific Officer | Jun 17 '24 | Buy | $33.58 | 30,000 | $1,007,490.00 | 30,000 | SEC Form 4 |
| CHILDS JOHN W | BHVN | Director | May 30 '24 | Buy | $35.58 | 28,000 | $996,240.00 | 2,311,341 | SEC Form 4 |
| Bailey Gregory | BHVN | Director | May 13 '24 | Buy | $34.19 | 15,000 | $512,877.00 | 1,615,071 | SEC Form 4 |
| CHILDS JOHN W | BHVN | Director | May 13 '24 | Buy | $35.17 | 28,500 | $1,002,470.40 | 2,283,341 | SEC Form 4 |
| Bailey Gregory | BHVN | Director | Apr 24 '24 | Buy | $39.18 | 25,503 | $999,169.29 | 1,600,071 | SEC Form 4 |
| CHILDS JOHN W | BHVN | Director | Apr 22 '24 | Buy | $41.00 | 24,391 | $1,000,031.00 | 24,391 | SEC Form 4 |
| CHILDS JOHN W | BHVN | Director | Apr 22 '24 | Buy | $41.00 | 97,560 | $3,999,960.00 | 4,096,512 | SEC Form 4 |
| CHILDS JOHN W | BHVN | Director | Apr 22 '24 | Buy | $41.00 | 73,170 | $2,999,970.00 | 2,254,841 | SEC Form 4 |
| Coric Vlad | BHVN | Chief Executive Officer | Apr 22 '24 | Buy | $41.00 | 121,951 | $4,999,991.00 | 1,788,417 | SEC Form 4 |
| Bailey Gregory | BHVN | Director | Apr 22 '24 | Buy | $41.00 | 48,780 | $1,999,980.00 | 1,574,568 | SEC Form 4 |
| Antonijevic Irina | BHVN | Director | Dec 29 '23 | Sell | $41.79 | 11,000 | $459,662.50 | 2,535 | SEC Form 4 |
Latest Biohaven Ltd. News
BHVN Breaking Stock News: Dive into BHVN Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 months ago
Flash News: OKX Launches 'Trade and Earn' Campaign Featuring 2,500,000 Ultiverse Tokens
PR Newswire
2 months ago
Advantech Releases FWA-3051, The Latest 1U Rackmount Edge Networking Solution with Intel® Xeon® D-2700/2800 Series
GlobeNewswire
2 months ago
Sustainable Construction Practices and Modular Techniques Drive Dry Construction Market to $127.69 Billion by 2029
GlobeNewswire
2 months ago
Hydrogen Storage Market Set to Hit $6.8 Billion by 2031, registering a solid CAGR of 23% - Exclusive Report by Coherent Market Insights
Insider Monkey
2 months ago
Shake Shack (SHAK) Rose after Strong Q4 Results
GlobeNewswire
2 months ago
Flash News: OKX to List Ultiverse's Token on its Perpetual Futures Market, Expanding Trading Options
PR Newswire
2 months ago
"Green Energy" Brings Charging Piles to Mountain Villages
GlobeNewswire
2 months ago
Global UV-Curable Adhesives Market Report 2024: Rising Demand in Electronics and Packaging Drives UV-Curable Adhesives Market to $605.4 Million by 2032
Compare BHVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BHVN Biohaven Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.